Objectives: To investigate the regulation of sclerostin (SOST) in osteoarthritis (OA) and its potential effects on articular cartilage degradation.
Introduction
The aetiology of knee osteoarthritis (OA) is multifactorial, and although ageing is strongly associated, other factors contribute. In particular altered biomechanics and joint instability commonly leads to "post-traumatic OA" within 10-15 years after joint injury in humans [1, 2] .
The central feature of OA is considered to be the progressive destruction of articular cartilage, however change occurs in all joint tissues. Subchondral bone thickening and marginal osteophytosis are classic features of OA, and together with synovitis correlate with pain [3] .
Focal loss of articular cartilage in OA may be linked to changes in the subjacent bone, through altered load transmission and/or direct signalling between the adjacent tissues [4] .
The Wnt-β-catenin signalling pathway has well-recognised roles in embryology and development, and is emerging as critical regulator of bone and cartilage homeostasis in the adult [5] [6] [7] [8] . Canonical Wnt signalling is initiated by binding to frizzled receptors and coreceptors, (low-density lipoprotein receptor (LRP) 5/6), which leads to β-catenin stabilization, nuclear translocation, and activation of target genes such as Wnt-induced signalling protein-1 (WISP1). Wnt signalling is modulated by soluble antagonists including dickkopf-1 (DKK1), secreted frizzled-related proteins (sFRPs), and sclerostin (SOST) [6] . There is a large body of evidence demonstrating the central role for Wnt signalling in regulating adult bone turnover, with increased β-catenin activity inducing bone production, and inhibition of soluble antagonists an emerging therapeutic approach for osteoporotic and inflammatory bone loss [7, 9] . In adult cartilage in contrast, increased Wnt-β-catenin stimulates tissue breakdown rather than formation [10] . WISP1 is increased in OA, and when over-expressed induces cartilage degradation by upregulating matrix metalloproteinases (MMPs) and aggrecanases [11] . The pro-degradative effects of Wnt-β-catenin are also driven through promotion of chondrocyte hypertrophy and the associated upregulation of MMPs [6, 8] . Induction of constitutive β-catenin activity in adult mouse chondrocytes causes progressive cartilage degeneration and M A N U S C R I P T
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4 increased subchondral bone density [12] . Circulating DKK1 levels negatively correlate with biomarkers of cartilage breakdown in OA patients [13] and sFRP3 knockout mice have augmented cartilage proteoglycan loss in a collagenase-induced instability model of arthritis [14] .
Collectively this data suggests that elevated β-catenin activity is a common mechanism in the excess bone formation and overlying cartilage loss in OA. However, the complexity of Wnt-β-catenin regulation and effects on joint tissues is demonstrated by the fact that constitutive inhibition of chondrocyte β-catenin activity also leads to OA in mice [15] . Increased circulating DKK1 (i.e reduced Wnt-β-catenin) is associated with worse cartilage degradation in rheumatoid patients [13] . DKK1 promotes chondrocyte apoptosis in vitro [16] , which may explain the reduction in severity in rat OA models with systemic DKK1 inhibition [17] . The conflicting data with DKK1 blockade being chondroprotective while sFRP3 ablation augments chondrolysis, may suggest distinct roles for different Wnt inhibitors in different tissues and/or disease states (e.g. degree of inflammation). The effect on OA of blocking SOST, the other important soluble inhibitor of Wnt signalling, has not been reported.
Sclerostin, is a member of the DAN/Cerberus protein family and acts to inhibit BMP secretion from cells in which it is co-expressed, and as a potent inhibitor of canonical Wnt signaling by binding to LRP5/6 [18, 19] . It is the failure to inhibit Wnt-β-catenin signaling that accounts for the characteristic high bone density phenotypes in patients with homozygous defects in SOST [20] , and in Sost knock out mice [21] . Sclerostin expression is down regulated by mechanical loading of bone [22] but can be induced by pro-inflammatory cytokines [23, 24] , indicating that SOST can regulate both mechanical and inflammatory bone remodeling. There is little information on changes in SOST in arthritis, with a reduction in the number of SOST-positive osteocytes noted in association with increased cortical bone density in the femoral neck of patients with hip OA [25] , and in zygapophyseal joints with M A N U S C R I P T
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OA and ankylosing spondylitis [26] . Recently it has been demonstrated that SOST is also expressed by chondrocytes in mineralized cartilage [27] , and in human end-stage OA [28] .
To date there has been no analysis of changes in SOST in subchondral bone in OA and how this relates to the overlying cartilage damage. Furthermore, the regulation of SOST expression by chondrocytes, the effects of SOST on chondrocytes and whether SOST plays any role in cartilage degradation has not previously been studied. The aim of this study is to investigate these questions to better define the role of SOST in OA.
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Materials and Methods
Animal models and human specimens
Four-year-old castrated male Merino sheep underwent unilateral medial meniscectomy (MEN) (n=6) or a sham procedure (arthrotomy alone; n=6) three months prior to euthanasia with institutional ethics approval (AEC832R/00) [29] . Coronal 5mm-thick osteochondral specimens spanning the width of the medial tibial plateau encompassing the region of maximal cartilage damage and adjacent unaffected tissues, were fixed for 24 hours (10% neutral-buffered formalin), decalcified (10% formic acid/5% formalin) and paraffin embedded [30] .
Ten-week-old male C57BL/6 mice underwent destabilization of the medial meniscus (DMM) and sham surgery in right and left knees, respectively [31, 32] , with institutional ethics approval (protocols 0051-005A and 0506-019A). Four mice were euthanised 1, 2 and 6 weeks after surgery. Sagittal sections every 40µ across the width of the medial femoro-tibial joint were evaluated [33] enabling intervening sections with maximal OA change to be used for immunohistochemistry.
Human specimens were obtained with informed consent and approval of the Northern Sydney Health Human Research Ethics Committee, from patients undergoing total knee replacement for OA. Sections (4µm) from formalin-fixed, decalcified, paraffin-embedded coronal osteochondral specimens spanning the width of the medial tibial plateaus and encompassing the focal area of maximal cartilage erosion from 9 patients were immunostained (see below).
Pooled residual articular cartilage from the tibial plateau was harvested from an additional 6 patients and RNA extracted [34] .
Histopathology and immunohistochemistry
Sections from ovine joints were stained with toluidine blue and fast green, and the cartilage degradation scored (BC and CBL) using a previously described grading system [30] . The cartilage damage was scored in two separate regions (Fig 1A) : area 1 = unprotected, and area 2 = normally protected by the meniscus, the latter experiencing increased loading and degeneration following meniscectomy while area 1 remains unaffected (Fig 1A) [35] . The density of subchondral bone in area 1 and 2 was quantified from digital images of haematoxylin and eosin stained serial sections. A region of interest 1.1 mm wide x 3.4 mm deep spanned the maximal depth of the subchondral bone plate (chondro-osseous junction to the beginning of trabecular bone). The % of this area containing eosin-stained bone was quantified (Image-Pro Plus 5.1; Media Cybernetics, Bethesda, USA), as a measure of "subchondral bone density".
Sections for immunostaining were dewaxed and rehydrated, and incubated in Protein-BlockSerum-Free (X909; DakoCytomation) for ten minutes at room temperature. Sections were immunolocalised overnight at 4°C with primary antibody or non-immune serum or IgG as negative controls, using conditions optimised from preliminary studies: rabbit anti-sclerostin (Abcam, UK) 1.25µg/ml; goat anti-sclerostin (R&D systems, USA) and rabbit anti-WISP1 (Santa Cruz, USA) 1µg/ml. Secondary antibody incubation and colour development were performed as described [35] . Coded digital images were evaluated independently by two observers (BC and CBL) and the number of positively stained cells in each region were quantified. The specificity of the anti-sclerostin antibody was demonstrated by pre-absorption with 10x concentration of recombinant human SOST for 2hr at room temperature before routine immunohistochemistry.
Ex-vivo cartilage explants culture
Full-depth articular cartilage explants (5-10mm 2 , ~40mg) from the trochlear groove of 6-12 month-old ovine knee joints were cultured in serum free media for 24 and 48 hours ± 10ng/mL IL-1α or 100ng/mL TNFα (PeproTech, Rocky Hill, NJ) [36] . The effect of SOST was examined by addition of 25 or 250ng/mL of rhSOST (R&D Systems, Minneapolis, USA) for 48 hours ± 10ng/mL IL-1α. At harvest the explants were blotted dry, weighed, and snapfrozen in liquid nitrogen for RNA extraction. Release of glycosaminoglycan (GAG) into the media was measured using dimethylmethylene blue and normalised to the explant wet weight [36] .
RNA extraction, reverse transcription and real-time quantitative PCR
Approximately 100mg of frozen ovine or human cartilage were fragmented in a MikroDismembrator (Braun Biotech International, Melsungen, Germany). Total RNA was extracted with TRIzol and isolated using the RNeasy kit (Qiagen, Australia) including an oncolumn DNase I (Qiagen) digestion, quantified with a Nanodrop 1000 spectrophotometer (Thermo Scientific, Waltham, USA), and samples with a 260/280 ratio >2.0 used for reverse transcription (RT). Changes in mRNA expression were quantified using real time qRT-PCR as described [37] using specific primer sets ( Table 1) . The "housekeeping genes" examined (GAPDH, HRPT, β-actin and ubiquitin) were all regulated by one or more of the experimental conditions (data not shown), and therefore samples were normalised using equal amounts of total RNA as recommended [38, 39] , and effects of treatment expressed as fold change from control.
Statistical analysis
Data is reported as mean with 95% confidence intervals (lower, upper). Ordinal data are presented graphically as mean with 95% confidence intervals. Because some data (e.g. gene expression) was not normally distributed, all treatment effects were assessed using nonparametric analysis (Mann-Whitney U test) with P < 0.05 considered significant.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Results
Sclerostin is increased in cartilage but decreased in subchondral bone in OA
Medial meniscectomy induced focal OA-like change in the sheep, including loss of cartilage proteoglycan, cartilage surface fibrillation and partial thickness erosion, and marginal osteophytosis ( Fig 1A) . Significant cartilage changes were restricted to the region previously protected by the meniscus that is subjected to high focal loading in meniscectomised joints (Area 2 -score 3.2 (2.4,3.9) vs 10.4 (8.6,12.2); p<0.001), with no change in Area 1 ( Fig 1B) .
In association with the overlying cartilage damage there was increased subchondral bone in (Fig 1D) , and the number of positive chondrocytes in the M A N U S C R I P T A C C E P T E D We confirmed the positive chondrocyte SOST immunostaining observed in sheep, in DMMinduced OA in mice and in late stage human OA (Fig. 2) . In sham-operated mouse joints, there was no SOST staining in non-calcified articular cartilage chondrocytes, although almost all chondrocytes in the calcified cartilage were immunopositive (Fig 2A) . At 2 weeks post-DMM, scattered chondrocytes in the non-calcified cartilage became SOST positive, and there was an increase in staining intensity in the calcified cartilage (Fig 2A) . In 3/9 human OA tibial plateaux, chondrocytes in the superficial cartilage zones, often in clusters, stained strongly for SOST (Fig 2B) . The antibody specificity was confirmed by osteocytes in subchondral and trabecular bone having typical SOST staining, and the lack of staining when IgG was substituted for the primary antibody (Fig 2B) .
Chondrocytes express Sost mRNA and it is regulated by IL-1
We investigated whether the SOST staining in chondrocytes was associated with local synthesis by the chondrocytes rather than diffusion of exogenous protein into the cartilage.
We detected SOST mRNA in chondrocytes in ovine cartilage, and from 2/6 human patients tested ( Fig 2C) . We examined whether the increase chondrocytes SOST in OA might be due to upregulated expression by inflammatory cytokines. In preliminary studies equivalent maximal GAG release from cartilage occurred with 10ng/ml IL-1α and 100ng/ml TNFα  data not shown   At these maximally effective doses, IL-1α induced a 9-fold (6.6,10.7) upregulation of SOST compared with control at 24 hours (Fig 3A; p<0.001), and this remained elevated at 48 hours (1.8-fold (1.3,2.2); p=0.093). This IL-1-induced increase in SOST mRNA was accompanied by increased chondrocyte SOST immuno-localization (Fig 3B) . In
contrast, TNFα did not alter chondrocyte SOST expression in ovine cartilage explants at either 24 or 48 hours (Fig 3A) .
Wnt-β-catenin signalling is altered in meniscectomy-induced OA in sheep
In light of SOST being an antagonist of Wnt-β-catenin signalling in bone, we examined whether WISP1, a down-stream indicator of β-catenin activity, was co-ordinately decreased in the sheep OA model. In sham-operated joints WISP1 was immunolocalised to osteocytes in the subchondral bone plate (Fig 4A) and trabecular bone (not shown). There was no difference in the number of WISP1-positive osteocytes between bone regions in shamoperated joints and no change following meniscectomy (Fig 4B) . WISP1 was immunolocalised to the chondrocytes in the superficial layer in sham-operated joints (Fig 4A) , and some hypertrophic chondrocytes in the calcified cartilage (not shown). Following meniscectomy there was no change in intensity or distribution of chondrocyte WISP1 staining in Area 1, however chondrocytes through the depth of the non-calcified cartilage showed strong staining in Area 2 ( Fig 4A) . Fig 4B) .
SOST regulates gene expression in normal cartilage
The co-localised increase in chondrocyte SOST and WISP1 staining in OA cartilage (Area 2)
were not consistent with the purported role of SOST as an inhibitor of Wnt-β-catenin signalling. We therefore investigated the effect of SOST on chondrocyte expression of (Fig 5A) . Concordant with this inhibition of Wnt signalling at 48 hours, SOST decreased COL2, ACAN and TIMP1 mRNA expression by a similar level at both doses ( Fig   5B) . MMP1 and ADAMTS4 mRNA levels were not significantly altered by SOST suggesting that the effects were not due to generalised cell toxicity. MMP13 expression was decreased only at the lowest dose while ADAMTS5 and TIMP3 were dose-dependently decreased.
SOST inhibits IL-1-induced cartilage degradation
The results in normal cartilage suggest that indeed SOST is a negative regulator of Wnt-β-catenin signalling and activity in chondrocytes. However SOST had effects on chondrocyte gene expression that would be considered "anti-anabolic" (decreased ACAN and COL2), "pro-catabolic" (decreased TIMP1 and TIMP3) as well as "anti-catabolic" (decreased MMP13 and ADAMTS5). In order to investigate the effect of SOST in an environment where cartilage catabolism is augmented, we co-cultured explants for 48 hours with SOST in the presence of 10ng/ml IL-1α. IL-1α induced the expected changes in chondrocyte gene expression, decreasing ACAN and COL2 while increasing MMP1, MMP13, ADAMTS4 and ADAMTS5 (Fig 6A) . These IL-1-induced changes were accompanied by increased GAG release and a concordant loss of toluidine blue staining of the cartilage (Fig 6B) . Importantly, SOST dose-dependently decreased IL-1α-induced GAG release into the media, with over 50% reduction at 250ng/ml (Fig 6B, 
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Discussion
Canonical Wnt signalling and increased β-catenin activity has been implicated in the process of cartilage degradation in OA [11, 40] . The current data from the sheep meniscectomy model of OA supports these previous studies, showing elevated chondrocyte WISP-1 staining.
Our detailed regional analysis enabled us to demonstrate that this increase in WISP-1 was restricted to the chondrocytes in the focal area of cartilage degradation, and was unaltered in the remaining cartilage or the subjacent bone. Previous studies have suggested conflicting roles for DKK1 and sFRP3 in regulating cartilage and bone changes in animal models of OA [14, 17] . SOST is also a potent Wnt antagonist and a key regulator of bone metabolism, but no previous publications have investigated whether it plays a role in global OA joint pathology. We have for the first time demonstrated an increase in SOST in chondrocytes restricted to the focal area of cartilage degradation in post-traumatic OA. In addition, we found a differential regulation in cartilage and bone, with a decrease in osteocyte SOST staining associated with increased subchondral plate thickening. Furthermore, we show that chondrocytes themselves express SOST which can be regulated by IL-1α but not TNFα.
SOST could act as an inhibitor of Wnt-β-catenin signalling in chondrocytes in vitro, and in the presence of IL-1α significantly regulate expression of cartilage matrix proteins, MMPs, ADAMTS and TIMPs, with a net result of reducing IL-1α-induced aggrecanolysis. Taken together, this data suggests that changes in SOST may play a role in the pathological progression of OA, promoting subchondral bone sclerosis but potentially inhibiting cartilage proteolysis.
Given that SOST is a potent antagonist of the Wnt-β-catenin pathway, it is difficult to reconcile the coincident increase in SOST and WISP-1 in OA cartilage. One possible explanation is that β-catenin is being activated in chondrocytes by prostaglandin-E2,
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16 independent of Wnt-signalling as described in other cell types [41] . Canonical regulation of β-catenin by Wnts is complex, with levels of different Wnts, receptors, inhibitors and intracellular ligands all contributing [42] . A decrease in one of these components may be offset by the increase in another, with a net abrogation of the expected action. Nevertheless, the increase in SOST in OA chondrocytes should be acting to decrease canonical signalling, and most data suggests that elevated chondrocyte β-catenin has a pro-catabolic effect on cartilage, stimulating MMP and ADAMTS synthesis via increased WISP-1 [11, 16] , and promoting chondrocyte hypertrophy which is associated with OA cartilage pathology [6, 8] .
As such, elevated chondrocyte SOST is likely to be at least partially chondroprotective, and in its absence an even greater increase in chondrocyte β-catenin activity, WISP1 and associated cartilage degradation would ensue. Our in vitro data support this hypothesis, with down regulation of β-catenin signalling, MMP and ADAMTS expression by SOST.
Consistent with a beneficial effect of Wnt antagonism, elevated circulating levels of DKK1 are negatively associated with serum markers of cartilage degradation in human OA [13] .
However, it would appear that some "appropriate" level of chondrocyte β-catenin activity is needed to maintain normal cartilage, as excessive inhibition [12] and in vitro treatment with DKK1 [16] , can induce chondrocyte apoptosis and cartilage breakdown.
The effect of SOST on Wnt signalling in OA cartilage/chondrocytes will be dependent on its binding to Lrp5/6. DKK1 can displace SOST from Lrp5/6 [43] , and a concurrent increase in both of these proteins in OA cartilage could potentiate effects of SOST outside the Lrp5/6-β-catenin pathway. SOST binds to Lrp4, and hypomorphic mutations in Lrp4 result in skeletal abnormalities in mice including polysyndactyly, possibly through interfering with BMP signalling [43] . SOST also functions as a BMP antagonist by inhibiting secretion from cells in which it is co-expressed [18] , and BMPs have potent effects on chondrogenesis,
17 chondrocyte maturation and anabolism [44] , as well as increasing DKK1 expression [45] .
Over expression of human SOST in mice leads not only to decreased bone density through inhibition of Wnt-β-catenin signalling, but also syndactyly consistent with inhibition of BMPs [46] . SOST can rapidly activate ERK1/2 signalling in osteoblasts by an undefined pathway [24] . These non-Wnt-dependent pathways may contribute to the effect of elevated SOST in OA chondrocytes, possibly promoting rather than inhibiting cartilage degradation.
Control of SOST expression by different regulatory elements in the proximal promoter is dependent on cell type [46] . Our in vitro data demonstrates that, at doses that induce cartilage degradation, IL-1α but not TNFα increased SOST expression. The lack of effect of TNFα on SOST mRNA levels in chondrocytes is interesting in light of the significant upregulation of SOST by TNFα in osteoblasts [24] , consistent with cell-specific regulation. Regulation of chondrocyte type II collagen and MMP expression by IL-1 have been reported to be independent of Wnt-β-catenin signalling [11, 47] . Nevertheless both IL-1 and TNF can regulate expression and activity of the Wnt-β-catenin pathway [16, 24] . Our data demonstrating a distinct difference between IL-1α and TNFα in SOST regulation while the two cytokines have similar effects on ACAN, COL2, MMP and ADAMTS expression (data not shown), is consistent with cytokine-driven cartilage catabolism being independent of Wnt-β-catenin. Chondrocyte-derived IL-1 has been implicated in OA cartilage degradation [48] , which could potentially account for the increase in SOST in OA cartilage. However, the very focal nature of the cartilage changes and altered SOST expression in our sheep OA model, suggests a more localized regulatory mechanism such as mechanical loading. In bone, SOST expression is strongly regulated by mechanical loading [22, 49] , and the decrease in SOST protein in the subchondral plate following meniscectomy is consistent with these previous studies. Despite the overlying cartilage also experiencing increased focal compressive Nevertheless, the fact that articular chondrocytes expressed SOST in OA in all three species suggests it is a common pathophysiological mechanism, and future studies should examine the temporal changes in SOST over the course of OA initiation and progression.
In conclusion, we have demonstrated that contrary to being an osteocyte-specific product,
SOST is expressed by articular chondrocytes and regulated by IL-1α. Importantly, chondrocyte SOST is focally increased in cartilage in OA while being decreased in the subjacent subchondral bone. While the role of SOST in regulating bone metabolism has been well established, we show for the first time that SOST is biologically active in chondrocytes, not only inhibiting Wnt-β-catenin signalling and catabolic MMP and ADAMTS expression, but also decreasing mRNA levels of key matrix components and enzyme inhibitors. Despite this mixed effect, SOST dose-dependently inhibited IL-1α-stimulated cartilage aggrecanolysis in vitro. These results implicate SOST in regulating the OA disease processes in both bone and cartilage, but suggest opposing effects by promoting disease-associated subchondral bone sclerosis while inhibiting degradation of cartilage. Increasing Wnt-β-catenin activity using antibodies to SOST (and DKK1) has potential in treating osteoporotic and inflammatory bone loss [50, 51] . While it is unlikely such therapeutic agents will enter cartilage to regulate chondrocyte SOST, given the multiple mechanisms of action of SOST in hours in serum free media ± 25 or 250ng/ml recombinant human sclerostin. Expression of (A)
Wnt-β-catenin pathway genes, and (B) matrix protein, metalloproteinase and tissue inhibitor genes. Data is expressed as fold change in expression compared with untreated control cultures (mean ± 95% confidence intervals; n = 22 replicates from 3 individual experiments).
Significant differences compared to control culture is indicated by the p-value. 
